Abstract
Activation by opioid receptors of cell proliferation was examined with fibroblast cell lines stably expressing either δ-opioid or μ-opioid receptors. Addition of [d-Ala2,d-Leu5]-enkephalin or [d-Pen2,d-Pen5]-enkephalin to Chinese hamster ovary (CHO) cells transfected with δ-opioid receptor cDNA resulted in an agonist concentration-dependent potentiation of fetal calf serum (FCS)-stimulated cell proliferation. This potentiation by δ-opioid agonists was antagonized by naloxone and was not observed with the κ-opioid receptor selective agonist U50,488 or the μ-opioid receptor selective agonist [d-Ala2,N-MePhe4,Gly-ol5]-enkephalin. This δ-opioid agonist effect was not observed at FCS concentrations >0.1% and could be blocked by pretreating cells with pertussis toxin, indicating that Gi/Go were involved in this action. In addition, δ-opioid agonists could potentiate CHO cell proliferation stimulated by those growth factors that are mediated by tyrosine kinase receptors (i.e., insulin, insulin-like growth factor 1, and fibroblast-derived growth factor b). This δ-opioid agonist potentiation of growth apparently was dependent on the level of δ-opioid receptors that were expressed and had cell-line selectivity. Activation of δ-opioid receptors expressed in Rat-1 or NIH3T3 fibroblast did not result in a modulation of the cell growth induced by FCS or by growth factors. Interestingly, in CHO cells transfected with μ-opioid receptor cDNA, activation with agonists did not produce a potentiation of FCS-stimulated proliferation. This lack of μ-opioid receptor effect was not due to the differences among CHO clones. In a CHO cell line transfected with both δ-opioid receptor cDNA and μ-opioid receptor cDNA, activation of δ- but not μ-opioid receptors resulted in a potentiation of growth. These data suggest that δ- and μ-opioid receptors in CHO cells activate similar but divergent second messenger pathways, resulting in the differential regulation of cell growth.
Footnotes
- Received September 13, 1995.
- Accepted September 23, 1996.
-
Send reprint requests to: Dr. Ping Yee Law, Department of Pharmacology, University of Minnesota, 3–249 Millard Hall, 435 Delaware Street, SE, Minneapolis, MN 55455. E-mail:ping{at}lenti.med.umn.edu
-
This research is supported in part by National Institute on Drug Abuse Grants DA07339 and DA05695.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|